Gemoscan Canada, Inc.

Gemoscan Canada, Inc.

April 12, 2011 13:17 ET

Gemoscan Canada Announces Entry Into Financial and Strategic Advisory Services Agreement

TORONTO, ONTARIO--(Marketwire - April 12, 2011) - Gemoscan Canada, Inc. ("Gemoscan") – (CNSX:GES) is pleased to announce that it has entered into a non-exclusive advisory services agreement (the "Agreement") with Borderline Capital Partners Inc. ("BCP") for the provision of financial and strategic advisory services ("Advisory Services") to the Company's management and board of directors. The term of the Agreement shall initially be for a ninety day period effective April 12, 2011, but is subject to renewal upon mutual agreement.

The Advisory Services to be provided by BCP include but are not limited to:

Assisting Gemoscan in structuring and entering into agreements for: Financing to better position Gemoscan for future growth; Sponsorship Financing which includes the potential for Gemoscan's graduation to a senior public stock exchange and Distribution Partnerships which contemplates expanding Gemoscan's commercial activities into territories outside of Canada.

Gemoscan will pay BCP a referral fee, in cash and stock warrants, equal to a percentage of any Financing and/or Sponsorship Financing that BCP assists Gemoscan in securing. As well BCP shall be granted an equity participation in any Distribution Partnership that BCP assists Gemoscan in securing. Any Financing, Sponsorship Financing or Distribution Partnership entered into by Gemoscan shall be at its sole discretion. Gemoscan will also pay BCP a monthly retainer in cash or common stock, which shall be shall be subtracted from any referral fee paid to BCP.


Founded in 2003 Gemoscan owns and markets the Hemocode System, a well-being assessment and treatment program that uses its own patented technology and services to detect and provide recommendations for the management of food intolerance and its often associated lifestyle affecting conditions such as fibromyalgia, chronic migraines and headaches, weight management, sleeplessness and others.

Gemoscan trades on the Canadian National Stock Exchange under the ticker GES and is quoted on the Munich Stock Exchange under the ticker 1GE.


BCP advises entrepreneurial, mid-market companies that are considering entering into critical strategic transactions and require the benefit of an experienced financial advisor to even the playing field and provide them with expertise in strategy, transaction structuring, and negotiation.

BCP's clients are globally situated and operate in both public and private capital. BCP advises on a wide range of transactions, including: mergers and acquisitions; buy-side advisory mandates; management buyouts; strategic partnerships, joint ventures and alliances; as well as various forms of divestitures, spin-offs and restructurings.

Borderline Capital Partners maintains a global presence through offices in New York, Toronto, Paris, Beijing and Moscow.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact, that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Contact Information